Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « AbsEn.i » - entrée « controlled »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
control < controlled < controlling  Facettes :

List of bibliographic references indexed by controlled

Number of relevant bibliographic references: 145.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000026 (2021) M. Bovet [Allemagne] ; D. Wadsack [Allemagne] ; F. Kosely [Allemagne] ; W. Zink [Allemagne] ; R. Zahn [Allemagne][Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm : Perimyocarditis and coagulopathy after administration of tocilizumab].
000049 (2021) Boghuma K. Titanji [États-Unis] ; Monica M. Farley [États-Unis] ; Ashish Mehta [États-Unis] ; Randi Connor-Schuler [États-Unis] ; Abeer Moanna [États-Unis] ; Sushma K. Cribbs [États-Unis] ; Jesse O'Shea [États-Unis] ; Kathryn Desilva [États-Unis] ; Bonnie Chan [États-Unis] ; Alex Edwards [États-Unis] ; Christina Gavegnano [États-Unis] ; Raymond F. Schinazi [États-Unis] ; Vincent C. Marconi [États-Unis]Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
000061 (2021) Neils Ben Quashie [Ghana] ; Nancy Odurowah Duah-Quashie [Ghana]Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries.
000065 (2021) Guobing Li [République populaire de Chine, États-Unis] ; Shasha Ruan [République populaire de Chine] ; Xiaolu Zhao [République populaire de Chine] ; Qi Liu [États-Unis] ; Yali Dou [États-Unis] ; Fengbiao Mao [République populaire de Chine]Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.
000091 (2021) Fatemeh Sadat Hosseini [Iran] ; Alireza Malektojari [Iran] ; Sara Ghazizadeh [Iran] ; Mehdi Hassaniazad [Iran] ; Parivash Davoodian [Iran] ; Habib Dadvand [Iran] ; Amin Reza Nikpoor [Iran] ; Sara Nikoofal-Sahlabadi [Iran] ; Sara Kahoori [Iran] ; Mojtaba Sepandi [Iran] ; Soheil Hassanipour [Iran] ; Mohammad Fathalipour [Iran]The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
000097 (2021) Jack Cook [États-Unis] ; Milton L. Pressler [États-Unis] ; Bharat Damle [États-Unis] ; Demissie Alemayehu [États-Unis] ; Charles A. Knirsch [États-Unis]The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin.
000104 (2021) Farah Daou [Liban] ; Gretta Abou-Sleymane [Liban] ; Danielle A. Badro [Liban] ; Nagham Khanafer [France] ; Mansour Tobaiqy [Arabie saoudite] ; Achraf Al Faraj [Liban]The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
000134 (2021) Fatemeh Roozbeh [Iran] ; Majid Saeedi [Iran] ; Reza Alizadeh-Navaei [Iran] ; Akbar Hedayatizadeh-Omran [Iran] ; Shahin Merat [Iran] ; Hannah Wentzel [Royaume-Uni] ; Jacob Levi [Royaume-Uni] ; Andrew Hill [Royaume-Uni] ; Amir Shamshirian [Iran]Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
000158 (2021) Hany M. Dabbous [Égypte] ; Manal H. El-Sayed [Égypte] ; Gihan El Assal [Égypte] ; Hesham Elghazaly [Égypte] ; Fatma F S. Ebeid [Égypte] ; Ahmed F. Sherief [Égypte] ; Maha Elgaafary [Égypte] ; Ehab Fawzy [Égypte] ; Sahar M. Hassany [Égypte] ; Ahmed R. Riad [Égypte] ; Mohamed A. Tageldin [Égypte]Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
000180 (2021) Ilad Alavi Darazam [Iran] ; Shervin Shokouhi [Iran] ; Mohamad Amin Pourhoseingholi [Iran] ; Seyed Sina Naghibi Irvani [Iran] ; Majid Mokhtari [Iran] ; Minoosh Shabani [Iran] ; Mahdi Amirdosara [Iran] ; Parham Torabinavid [Iran] ; Maryam Golmohammadi [Iran] ; Sayedpayam Hashemi [Iran] ; Arsalan Azimi [Iran] ; Mohammad Hossein Jafarazadeh Maivan [Iran] ; Omidvar Rezaei [Iran] ; Alireza Zali [Iran] ; Mohammadreza Hajiesmaeili [Iran] ; Hadiseh Shabanpour Dehbsneh [Iran] ; Akram Hoseyni Kusha [Iran] ; Maryam Taleb Shoushtari [Iran] ; Negar Khalili [Iran] ; Azam Soleymaninia [Iran] ; Latif Gachkar [Iran] ; Ali Khoshkar [Iran]Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.
000189 (2021) Kirill Alekseyev [États-Unis] ; Lidiya Didenko [États-Unis] ; Bilal Chaudhry [États-Unis]Rhinocerebral Mucormycosis and COVID-19 Pneumonia.
000223 (2021) Jessica M. Franklin [États-Unis] ; Kueiyu Joshua Lin [États-Unis] ; Nicolle M. Gatto [États-Unis] ; Jeremy A. Rassen [États-Unis] ; Robert J. Glynn [États-Unis] ; Sebastian Schneeweiss [États-Unis]Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19.
000227 (2021) Iwein Gyselinck [Belgique] ; Wim Janssens [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique]Rationale for azithromycin in COVID-19: an overview of existing evidence.
000230 (2021) Faryal Khamis [Oman] ; Hanan Al Naabi [Oman] ; Adil Al Lawati [Oman] ; Zaiyana Ambusaidi [Oman] ; Mariam Al Sharji [Oman] ; Umkulthum Al Barwani [Oman] ; Nenad Pandak [Oman] ; Zakariya Al Balushi [Oman] ; Maher Al Bahrani [Oman] ; Issa Al Salmi [Oman] ; Ibrahim Al-Zakwani [Oman]Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
000231 (2021) Venkata R. Emani [États-Unis] ; Sanjeev Goswami [États-Unis] ; Dheeraj Nandanoor [États-Unis] ; Shaila R. Emani [États-Unis] ; Nidhi K. Reddy [États-Unis] ; Raghunath Reddy [États-Unis]Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
000310 (2021) Silvia Molino [Espagne] ; Andrea Pisarevsky [Argentine] ; Fabiana Lopez Mingorance [Argentine] ; Patricia Vega [Argentine] ; Juan Pablo Stefanolo [Argentine] ; Julieta Repetti [Argentine] ; Guillermina Ludue A [Argentine] ; Pablo Pepa [Argentine] ; Juan Ignacio Olmos [Argentine] ; Marcelo Rodriguez Fermepin [Argentine] ; Tatiana Uehara [Argentine] ; Sonia Villapol [États-Unis] ; Tor Savidge [États-Unis] ; Todd Treangen [États-Unis] ; Elisa Viciani [Italie] ; Andrea Castagnetti [Italie] ; Maria Marta Piskorz [Argentine]Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial.
000321 (2021) Zakariya Kashour [Canada] ; Tarek Kashour ; Danielle Gerberi [États-Unis] ; Imad M. Tleyjeh [Arabie saoudite, États-Unis]Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
000424 (2021) Petri J. Vainio [Finlande] ; Pauliina Hietasalo [Finlande] ; Anna-Liisa Koivisto [Finlande] ; Susanna K Ri Inen [Finlande] ; Jari Turunen [Finlande] ; Mika Virtala [Finlande] ; Jouni Vuorinen [Finlande] ; Mika Scheinin [Finlande]Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
000429 (2021) Vincent Dubée [France] ; Pierre-Marie Roy [France] ; Bruno Vielle [France] ; Elsa Parot-Schinkel [France] ; Odile Blanchet [France] ; Astrid Darsonval [France] ; Caroline Lefeuvre [France] ; Chadi Abbara [France] ; Sophie Boucher [France] ; Edouard Devaud [France] ; Olivier Robineau [France] ; Patrick Rispal [France] ; Thomas Guimard [France] ; Emma D'Anglejean [France] ; Sylvain Diamantis [France] ; Marc-Antoine Custaud [France] ; Isabelle Pellier [France] ; Alain Mercat [France]Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial.
000437 (2021) Hozaifa Khalil Elsawah [Égypte] ; Mohamed Ahmed Elsokary [Égypte] ; Mahmoud Gamal Elrazzaz [Égypte] ; Ahmed Hanei Elshafie [Égypte]Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials.
000438 (2021) Bugra Han Egeli [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Alfred H J. Kim [États-Unis] ; Jean W. Liew [États-Unis]Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "controlled" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "controlled" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    controlled
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021